http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005101531-A1

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78
filingDate 2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_923cfb0612d8b5c968aa090cb692c235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac259d2dbff38141f903eeaefaca820e
publicationDate 2005-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2005101531-A1
titleOfInvention Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution
abstract The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein can be a monomer or a polymer like a dimer, trimer or a tetramer of a human recombinant gelatin-like protein having an isolectric point of less than 8. The resulting gelatin-like proteins provide a method to control the clearance rate of a plasma expander by its molecular weight. Preferably the gelatin-like proteins have a low hydroxyproline content which prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. An additional advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7459431-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009072508-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005119170-A1
priorityDate 2002-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4539204-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2827419-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6413742-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6150081-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416339
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127843891
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4737
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID83228
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129841714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID269023
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54075331
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10351092
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226416340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128937483
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128603946
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID588
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226413167
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400268
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69248

Total number of triples: 43.